SPARC (Sun Pharma Advanced Research Company) SPARC
Sun Pharma group's pure R&D company developing novel drugs and delivery platforms for out-licensing
Mapped in 1 theme: Pharmaceuticals.
Where SPARC (Sun Pharma Advanced Research Company) sits in the supply chain
SPARC (Sun Pharma Advanced Research Company) appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Specialty & innovation (R&D)
Emerging entrantOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 76 | 72 | 1,879 |
| Net profit | −387 | −343 | 1,553 |
Latest-year revenue ₹1,879 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Pure-play exposure to Indian drug discovery with Sun Pharma backing
- Won a US FDA priority review voucher with Sezaby (Feb 2026) and sold it for US$195m
Risks
- No recurring revenue - FY26 profit is the one-off voucher; the business is otherwise loss-making
- Binary clinical outcomes and past pipeline setbacks
- Depends on licensing partners and funding
Common questions
What does SPARC (Sun Pharma Advanced Research Company) do?
Sun Pharma group's pure R&D company developing novel drugs and delivery platforms for out-licensing.
Where does SPARC (Sun Pharma Advanced Research Company) sit in the supply chain?
SPARC (Sun Pharma Advanced Research Company) (NSE: SPARC) is mapped in 1 supply-chain layer: Specialty & innovation (R&D) (Pharmaceuticals).
Who are SPARC (Sun Pharma Advanced Research Company)'s peers?
In the Specialty & innovation (R&D) layer of Pharmaceuticals: Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, Wockhardt, Zydus Lifesciences and Lupin.
What is SPARC (Sun Pharma Advanced Research Company)'s market cap and valuation?
As of 30 Oct 2026: market cap ₹5,718 Cr, P/E 3.6x, ROCE 164.0%, ROE 279.0%, dividend yield 0%.